argenex (NASDAQ:ARGX) Announces Earnings Results

argenex (NASDAQ:ARGX) released its earnings results on Friday. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36, Zacks reports. argenex had a net margin of 32.19% and a return on equity of 43.59%. The firm had revenue of $1.75 billion during the quarter.

argenex Trading Down 0.7%

Shares of ARGX traded down $6.54 during trading hours on Friday, hitting $869.22. The company had a trading volume of 75,220 shares, compared to its average volume of 351,665. The company has a market capitalization of $54.67 billion, a PE ratio of 33.44, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44. argenex has a one year low of $661.85 and a one year high of $1,072.75. The company’s fifty day moving average price is $956.17 and its two-hundred day moving average price is $885.45.

Analysts Set New Price Targets

ARGX has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday. UBS Group upgraded argenex from a “neutral” rating to a “buy” rating and upped their price objective for the company from $960.00 to $1,400.00 in a research report on Wednesday, August 26th. Jefferies Financial Group reiterated a “buy” rating on shares of argenex in a research report on Monday, September 14th. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of argenex in a research note on Friday, October 9th. Finally, Robert W. Baird boosted their price target on argenex from $823.00 to $861.00 and gave the stock a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,148.95.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported third-quarter revenue of approximately $1.75 billion, with product net sales up 54% year over year to $1.7 billion. Earnings of $7.80 per share exceeded the $7.44 consensus estimate, while operating profit reached $486 million, or a 28% margin. Argenx SE Stock Falls Despite $1.7 Billion Sales and Profit Growth
• Positive Sentiment: Jefferies said the recent weakness may create an attractive entry point and maintained a favorable view of argenx’s setup through year-end 2026. Jefferies Analyst Commentary
• Neutral Sentiment: Robert W. Baird raised its price target from $823 to $861 but retained a neutral rating, implying limited upside at the reported share price. Royal Bank of Canada separately cut its target, underscoring mixed analyst sentiment. Robert W. Baird Analyst Ratings RBC Price Target Update
• Negative Sentiment: A surprise testing setback in a VYVGART-related study for Sjögren’s syndrome raised concerns about the breadth and timing of argenx’s pipeline expansion. Because VYVGART is the company’s primary commercial growth driver, the news overshadowed the quarterly earnings beat and strong sales growth. Argenx Testing Setback

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.